Navigation Links
FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
Date:4/23/2008

may cause sudden death and serious cardiovascular adverse events. These events have also been reported rarely with amphetamine use.

VYVANSE was generally well tolerated in clinical studies. The most common side effects reported in studies of VYVANSE were: children - decreased appetite, difficulty falling asleep, stomachache, and irritability; adult - decreased appetite, difficulty falling asleep, and dry mouth.

Aggression, new abnormal thoughts/behaviors, mania, growth suppression, worsening of motion or verbal tics, and Tourette's syndrome have been associated with use of drugs of this type. Tell the doctor if you or your child has blurred vision while taking VYVANSE.

Shire PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act of 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's r
'/>"/>

SOURCE Shire PLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
2. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
3. Medicare Approves in Home Sleep Apnea Testing
4. 3SBio Inc. Approves Share Repurchase Program
5. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
6. FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder
7. FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
8. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
9. FDA Approves New Mechanism of Action Labeling for Ranexa(R)
10. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
11. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Charm Sciences is pleased to announce that ... Aflatoxin M1 in raw commingled milk is the first ... The peer reviewed report of the validation by Technology ... and Fisheries Research (ILVO-T&V) has been published by the ... most toxic aflatoxin and a known carcinogen, can be ...
(Date:12/19/2014)... , Dec. 19, 2014 Bina Technologies, Inc. ... announced today that they have been acquired by Roche ... is a privately held company that provides a big ... generation sequencing (NGS) data for the academic and translational ... Sequencing Unit, and will continue to focus on development ...
(Date:12/19/2014)... December 18, 2014 Today, ... its pilot production facility and future company headquarters ... produce innovative new materials that safely and effectively ... only because of its historic, strong support for ... to attract leading edge, technology-based companies such as ...
(Date:12/19/2014)... iLab Solutions, the global leader in ... Bryant as the new Director of Institutional Implementations and ... These two new leadership positions were created to support ... that iLab continues to meet the needs of its ... iLab has been deployed at over 450 core facilities ...
Breaking Biology Technology:Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2
... Sept. 19 NPS,Pharmaceuticals, Inc. (Nasdaq: NPSP ... Administration,s Office of Orphan Products Development has granted,orphan ... for,injection) for the treatment of hypoparathyroidism, a rare ... FDA-approved therapy. Hypoparathyroidism afflicts approximately 65,000 people ...
... NeurogesX, Inc.,(Nasdaq: NGSX ), a biopharmaceutical company ... it is scheduled to present,at the 2007 UBS Global ... President and Chief Executive Officer, and Jeffery,Tobias, Chief Medical ... September 25, 2007 Time: 9:00 a.m. ...
... Sept. 19 The Pittsburgh Life Sciences,Greenhouse ... life,sciences industry on a fast track for ... in Coventina Healthcare Enterprises, Inc., a medical,device ... Frequency),and multi-modal treatment systems for research, rehabilitation, ...
Cached Biology Technology:PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism 2PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism 3NeurogesX to Present at UBS 2007 Global Life Sciences Conference 2NeurogesX to Present at UBS 2007 Global Life Sciences Conference 3The PLSG Invests $150,000 in Coventina Healthcare Enterprises, Inc., Its Eighth Company Relocation to Pittsburgh 2The PLSG Invests $150,000 in Coventina Healthcare Enterprises, Inc., Its Eighth Company Relocation to Pittsburgh 3
(Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today ... differences in genetic ancestry of individuals from across ... immigrants first arrived more than four hundred years ago, ... as a meeting place for peoples from different continents. ... mixing of peoples with African, European, and American origins ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. ... the adoption of multimodal biometric systems. Multimodal biometric ... individual for verification and identification purposes. This helps ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... PITTSBURGH, Jan. 11 A drug that is already ... effective secondary treatment for a rare tumor of the gastrointestinal ... University of Pittsburgh Cancer Institute (UPCI). The findings , ... Jan. 1 issue of Cancer Research . ...
... Rockville, Md., January 11, 2010 New standards to ... key ingredients widely used in infant formulas and a ... in the Food Chemicals Codex (FCC), an internationally recognized ... standards are for three nucleotides, present in breast milk ...
... Baltic Sea, threatening artefacts of the area,s cultural heritage. ... the unfortunate spread is due to climate change, and ... which archaeological remains are at risk. The shipworm is ... only 10 years, and while it has avoided the ...
Cached Biology News:Drug shows promise as new treatment for gut tumor 2Quality and safety of infant formulas, functional foods enhanced by new standards 2Quality and safety of infant formulas, functional foods enhanced by new standards 3Shipworm threatens archaeological treasures 2
Any form, any size, any number of mutageneses. ExonBio provides the best service with double sequecing to make sure the success of the mutagenesis....
Loading Buffer...
Request Info...
Request Info...
Biology Products: